JP7548906B2 - ボリナンセリンの重水素化形態および誘導体 - Google Patents

ボリナンセリンの重水素化形態および誘導体 Download PDF

Info

Publication number
JP7548906B2
JP7548906B2 JP2021535751A JP2021535751A JP7548906B2 JP 7548906 B2 JP7548906 B2 JP 7548906B2 JP 2021535751 A JP2021535751 A JP 2021535751A JP 2021535751 A JP2021535751 A JP 2021535751A JP 7548906 B2 JP7548906 B2 JP 7548906B2
Authority
JP
Japan
Prior art keywords
deuterium
compound
pharma
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515156A5 (enExample
JP2022515156A (ja
Inventor
スコット ワイントローブ，
スコット エル． ハーベソン，
Original Assignee
テラン バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テラン バイオサイエンシズ インコーポレイテッド filed Critical テラン バイオサイエンシズ インコーポレイテッド
Publication of JP2022515156A publication Critical patent/JP2022515156A/ja
Publication of JP2022515156A5 publication Critical patent/JP2022515156A5/ja
Priority to JP2024147359A priority Critical patent/JP2024163142A/ja
Application granted granted Critical
Publication of JP7548906B2 publication Critical patent/JP7548906B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021535751A 2018-12-21 2019-12-20 ボリナンセリンの重水素化形態および誘導体 Active JP7548906B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024147359A JP2024163142A (ja) 2018-12-21 2024-08-29 ボリナンセリンの重水素化形態および誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862784056P 2018-12-21 2018-12-21
US62/784,056 2018-12-21
PCT/US2019/067885 WO2020132461A1 (en) 2018-12-21 2019-12-20 Deuterated forms and derivatives of volinanserin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024147359A Division JP2024163142A (ja) 2018-12-21 2024-08-29 ボリナンセリンの重水素化形態および誘導体

Publications (3)

Publication Number Publication Date
JP2022515156A JP2022515156A (ja) 2022-02-17
JP2022515156A5 JP2022515156A5 (enExample) 2022-10-21
JP7548906B2 true JP7548906B2 (ja) 2024-09-10

Family

ID=71101633

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535751A Active JP7548906B2 (ja) 2018-12-21 2019-12-20 ボリナンセリンの重水素化形態および誘導体
JP2024147359A Pending JP2024163142A (ja) 2018-12-21 2024-08-29 ボリナンセリンの重水素化形態および誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024147359A Pending JP2024163142A (ja) 2018-12-21 2024-08-29 ボリナンセリンの重水素化形態および誘導体

Country Status (14)

Country Link
US (2) US20220106272A1 (enExample)
EP (1) EP3897507A4 (enExample)
JP (2) JP7548906B2 (enExample)
KR (1) KR20210124976A (enExample)
CN (1) CN113747870B (enExample)
AU (1) AU2019403391A1 (enExample)
BR (1) BR112021012082A8 (enExample)
CA (1) CA3124399A1 (enExample)
EA (1) EA202191731A1 (enExample)
IL (1) IL284201A (enExample)
MX (1) MX2021007437A (enExample)
SG (1) SG11202106692UA (enExample)
WO (1) WO2020132461A1 (enExample)
ZA (1) ZA202104656B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115057774A (zh) * 2022-04-28 2022-09-16 北京绮一舟新材料技术有限公司 一种α-氘代羧酸衍生物类化合物及氘代药物的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020569A1 (en) 2007-08-06 2009-02-12 Merck & Co., Inc. Treatment of psychosis with a 5ht2a antagonist and a metabotropic glutamate receptor agonist or potentiator
JP2014524888A (ja) 2011-05-23 2014-09-25 サノフイ Ｎ−アルキル基を含有するジュウテリウム化化合物の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570961C (en) * 2004-06-21 2015-09-01 University Of Mississippi Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US8609673B2 (en) * 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
WO2012039660A1 (en) * 2010-09-20 2012-03-29 A. Carlsson Research Ab Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
LT3135656T (lt) * 2011-06-20 2019-04-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
WO2014145718A2 (en) * 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
WO2018023009A1 (en) * 2016-07-29 2018-02-01 Concert Pharmaceuticals, Inc. Deuterated lurasidone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020569A1 (en) 2007-08-06 2009-02-12 Merck & Co., Inc. Treatment of psychosis with a 5ht2a antagonist and a metabotropic glutamate receptor agonist or potentiator
JP2014524888A (ja) 2011-05-23 2014-09-25 サノフイ Ｎ−アルキル基を含有するジュウテリウム化化合物の製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAS 登録番号1217617-73-6，REGISTRY （STN） [online]，2010年04月09日，検索日：2023年9月27日
Journal of Pharmaceutical and Biomedical Analysis，2014年，88，579-583
Journal of the American Chemical Society，2012年，134，12239-12244
Organic Square， No.33，2010年09月，2-3，https://labchem-wako.fujifilm.com/jp/journal/docs/org33.pdf，［検索日2023年10月2日］

Also Published As

Publication number Publication date
SG11202106692UA (en) 2021-07-29
IL284201A (en) 2021-08-31
JP2024163142A (ja) 2024-11-21
KR20210124976A (ko) 2021-10-15
AU2019403391A1 (en) 2021-08-05
US20250066302A1 (en) 2025-02-27
BR112021012082A8 (pt) 2023-03-21
US20220106272A1 (en) 2022-04-07
WO2020132461A1 (en) 2020-06-25
EP3897507A1 (en) 2021-10-27
CA3124399A1 (en) 2020-06-25
BR112021012082A2 (pt) 2021-08-31
CN113747870A (zh) 2021-12-03
CN113747870B (zh) 2025-08-01
EP3897507A4 (en) 2022-09-14
JP2022515156A (ja) 2022-02-17
MX2021007437A (es) 2021-09-08
ZA202104656B (en) 2022-10-26
EA202191731A1 (ru) 2021-10-28

Similar Documents

Publication Publication Date Title
AU2013296627C9 (en) Deuterated ibrutinib
US8575221B2 (en) Derivatives of dimethylcurcumin
EP3377179B1 (en) Deuterated epi-743
JP2023539125A (ja) 有機化合物
JP2024163142A (ja) ボリナンセリンの重水素化形態および誘導体
JP2021519276A (ja) Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用
WO2018005328A1 (en) Deuterated bictegravir
US10385042B2 (en) Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
US20140128469A1 (en) Deuterated n-butyl bumetanide
EP3416629A1 (en) Deuterated gft-505
US20160214995A1 (en) Substituted thienotriazolodiazapines
US10843993B2 (en) Deuterated idebenone
WO2016061488A1 (en) Amine reuptake inhibitors
WO2020092604A1 (en) Deuterated pitolisant
US20160009732A1 (en) Deuterated pacritinib
KR101900498B1 (ko) 치환된 아이소인돌린-1,3-다이온 유도체
WO2014150044A1 (en) Amine reuptake inhibitors
EP2804857A1 (en) Deuterated alpha-lipoic acid
WO2010036773A1 (en) Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240829

R150 Certificate of patent or registration of utility model

Ref document number: 7548906

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150